Jentadueto Xr
Developed to mitigate elevated blood glucose to support long-term metabolic health and target insulin receptor action.
- Category
- Diabetes Management
- Active ingredients
- Linagliptin · Metformin
- Route
- Oral use
- Form
- Tablet
- Strengths
- 5mg + 1000mg
Prescription and consultation requirements for Jentadueto Xr vary by destination and are determined by the fulfilment partner.
Jentadueto Xr details
- Condition
- Type 2 Diabetes Mellitus
- Alternative names
- linagliptin, metformin
- Therapeutic class
- DPP-4 Inhibitor, Biguanide Combination
- Pharmacological class
- Antidiabetic Combination
- Contraindications
- severe renal impairment; acute metabolic acidosis; diabetic ketoacidosis
- Minor side effects
- diarrhoea; nausea; headache
- Moderate side effects
- stuffy nose; metallic taste; flatulence
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Boehringer Ingelheim
- Onset Time
- 1–2 weeks
- Duration
- 24 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Contrast Media; Alcohol; Rifampin
- Age restrictions
- Approved for adults.
Serious side effects
lactic acidosis, requires immediate medical attention; acute pancreatitis, requires immediate medical attention
Patient summary
developed to mitigate elevated blood glucose to support long-term metabolic health and target insulin receptor action.
Mechanism of action
Metformin lowers liver glucose output while linagliptin increases active inkretin hormones to optimise insulin output.
Pregnancy and breastfeeding
TGA Category C: Use if benefit outweighs risk. Avoid in late term. Breastfeeding: Not recommended.